Valneva SE (“Valneva” or “the Company”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, today announced that all resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting held in Paris on June 27, 2019.